Coyle, C;
Cafferty, FH;
Langley, RE;
(2016)
Aspirin and Colorectal Cancer Prevention and Treatment: Is It for Everyone?
Current Colorectal Cancer Reports
, 12
(1)
pp. 27-34.
10.1007/s11888-016-0306-9.
Preview |
Text
art%3A10.1007%2Fs11888-016-0306-9.pdf - Published Version Download (358kB) | Preview |
Abstract
There is now a considerable body of data supporting the hypothesis that aspirin could be effective in the prevention and treatment of colorectal cancer, and a number of phase III randomised controlled trials designed to evaluate the role of aspirin in the treatment of colorectal cancer are ongoing. Although generally well tolerated, aspirin can have adverse effects, including dyspepsia and, infrequently, bleeding. To ensure a favourable balance of benefits and risks from aspirin, a more personalised assessment of the advantages and disadvantages is required. Emerging data suggest that tumour PIK3CA mutation status, expression of cyclo-oxygenase-2 and human leukocyte antigen class I, along with certain germline polymorphisms, might all help to identify individuals who stand to gain most. We review both the underpinning evidence and current data, on clinical, molecular and genetic biomarkers for aspirin use in the prevention and treatment of colorectal cancer, and discuss the opportunities for further biomarker research provided by ongoing trials.
| Type: | Article |
|---|---|
| Title: | Aspirin and Colorectal Cancer Prevention and Treatment: Is It for Everyone? |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1007/s11888-016-0306-9 |
| Publisher version: | http://dx.doi.org/10.1007/s11888-016-0306-9 |
| Language: | English |
| Additional information: | © The Author(s) 2016. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
| Keywords: | Aspirin, Acetylsalicylic acid, NSAID, Colorectal cancer, Chemoprevention, Secondary prevention, Primary prevention, Adjuvant therapy, Bleeding, PIK3CA, BRAF, Single-nucleotide polymorphism, Human leukocyte antigen |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy > Pharmacology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology > MRC Clinical Trials Unit at UCL |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/1476862 |
Archive Staff Only
 |
View Item |
